Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X – Autism-Related Disorders

Shared clinical phenotypes and underlying pathophysiology of Autism-Related Disorders such as Fragile X and Rett syndrome, indicates that ANAVEX 2-73 could be of interest to investigate clinically in these disorders NEW YORK, NY – June 6, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics…